

# Protocol

## Extracorporeal Photopheresis

(80136)

<b>Medical Benefit</b>		<b>Effective Date:</b> 01/01/15	<b>Next Review Date:</b> 09/20
<b>Preauthorization</b>	No	<b>Review Dates:</b> 05/09, 03/10, 09/10, 03/11, 03/12, 03/13, 03/14, 09/14, 09/15, 09/16, 09/17, 09/18, 09/19	

### **Preauthorization is not required.**

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

<b>Populations</b>	<b>Interventions</b>	<b>Comparators</b>	<b>Outcomes</b>
Individuals: <ul style="list-style-type: none"> <li>Who are heart transplant recipients who experience acute graft rejection refractory to immunosuppression</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are heart transplant recipients who experience recurrent and/or refractory graft rejection</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are heart transplant recipients who require prophylaxis to prevent graft rejection</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are lung transplant recipients who experience acute graft rejection</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are lung transplant recipients who have bronchiolitis obliterans syndrome refractory to corticosteroids</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are liver transplant recipients who experience graft rejection</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Extracorporeal photopheresis</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Medical management</li> <li>Immunosuppression</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>

Populations	Interventions	Comparators	Outcomes
Individuals: • Who are kidney transplant recipients who experience recurrent graft rejection	Interventions of interest are: • Extracorporeal photopheresis	Comparators of interest are: • Medical management • Immunosuppression	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • Who have acute or chronic graft-versus-host-disease refractory to medical therapy	Interventions of interest are: • Extracorporeal photopheresis	Comparators of interest are: • Medical management • Immunosuppression	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • Who have autoimmune diseases	Interventions of interest are: • Extracorporeal photopheresis	Comparators of interest are: • Medical management • Immunosuppression	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • Who have advanced-stage (stage III or IV) cutaneous T-cell lymphoma	Interventions of interest are: • Extracorporeal photopheresis	Comparators of interest are: • Medical management • Immunosuppression	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • Who have refractory or progressive early-stage (stage I or II) cutaneous T-cell lymphoma	Interventions of interest are: • Extracorporeal photopheresis	Comparators of interest are: • Medical management • Immunosuppression	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity

## DESCRIPTION

Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory procedure that involves the following three steps: (1) the patient's blood is collected into a centrifuge system that separates the leukocyte-rich portion (buffy coat) from the rest of the blood; (2) the photosensitizer agent 8-methoxypsoralen is added to the lymphocyte fraction, which is then exposed to ultraviolet-A (320-400 nm wavelength) light at a dose of 1 to 2 J/cm<sup>2</sup>; and (3) the light-sensitized lymphocytes are reinfused into the patient. The use of ECP has been investigated for patients needing treatment for organ rejection after solid organ, transplant graft-versus-host disease (GVHD), autoimmune diseases, and T-cell lymphoma.

## SUMMARY OF EVIDENCE

### GRAFT REJECTION AFTER SOLID ORGAN TRANSPLANT

#### Heart Transplant

For individuals who are heart transplant recipients who experience acute graft rejection refractory to immunosuppression who receive ECP, the evidence includes a small randomized controlled trial (RCT). Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. The small RCT, while suggesting similar outcomes for ECP and corticosteroids, is insufficient to permit conclusions on the utility of ECP. Studies with more patients and longer follow-up are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are heart transplant recipients who experience recurrent and/or refractory graft rejection who receive ECP, the evidence includes a comparative study and small case series. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Current evidence is consistent on the beneficial effect of ECP for cardiac transplant patients with graft rejection refractory to standard therapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are heart transplant recipients who require prophylaxis to prevent graft rejection who receive ECP, the evidence includes a small RCT. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. The small randomized trial is insufficient to permit conclusions on the utility of ECP. Studies with more patients and longer follow-up are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### Lung Transplant

For individuals who are lung transplant recipients who experience acute graft rejection who receive ECP, the evidence includes a small retrospective study and small case series. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Current evidence is very limited and any conclusions drawn lack certainty. A prospective, randomized trial is needed specifically evaluating the treatment of patients with acute graft rejection. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are lung transplant recipients with bronchiolitis obliterans syndrome refractory to corticosteroids who receive ECP, the evidence includes a prospective study and numerous retrospective analyses. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Studies have shown inconsistent results across bronchiolitis obliterans syndrome grades. Prospective, RCTs are necessary with analyses stratified by syndrome grade. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### Liver Transplant

For individuals who are liver transplant recipients who experience graft rejection and receive ECP, the evidence includes a small nonrandomized study, a retrospective study, and a case series. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Current evidence does not permit conclusions on the utility of ECP in this population. There is a need for RCTs comparing immunosuppressive therapy alone with immunosuppressive therapy with ECP. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### Kidney Transplant

For individuals who are kidney transplant recipients who experience recurrent graft rejection who receive ECP, the evidence includes a small prospective study and numerous case reports. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Current evidence does not permit conclusions on the effect of ECP on net health outcome. RCTs, comparing immunosuppressive therapy with immunosuppressive therapy using ECP and examining histologic confirmation of treatment response, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### Graft-Versus-Host Disease

For individuals who have acute or chronic graft-versus-host-disease (GVHD) refractory to medical treatment who receive ECP, the evidence includes systematic reviews, retrospective studies, and case series. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Current evidence has consistently shown that ECP reduces the incidence of GVHD that is unresponsive to standard therapy. Additionally, there is a lack of other treatment options for these patients; adverse events related to ECP are minimal;

and, if there is a response to ECP, patients may be able to reduce or discontinue treatment with corticosteroids and other immunosuppressive agents. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Clinical input obtained in 2014 supported the use of ECP in patients with refractory acute GVHD.

#### Autoimmune Disease

For individuals who have autoimmune diseases (e.g., cutaneous or visceral manifestations of autoimmune diseases including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, and Crohn disease) who receive ECP, the evidence includes isolated RCTs, small prospective and retrospective studies, and case reports. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. The current literature assessing the various autoimmune diseases is not sufficiently robust to support conclusions. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### T-Cell Lymphoma

For individuals who have advanced-stage (stage III or IV) cutaneous T-cell lymphoma (CTCL) who receive ECP, the evidence includes a systematic review and numerous small case series. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Evidence from these small case series has shown a favorable response to ECP treatment and an increase in survival in a proportion of these patients. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have refractory or progressive early-stage (stage I or II) CTCL who receive ECP, the evidence includes a systematic review. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Given the unfavorable prognosis for patients with early-stage CTCL that progresses on nonsystemic therapies, the relative lack of adverse events with ECP compared with other systemic treatments, and the good response rates often observed with ECP, this therapy is an option for those with refractory or progressive early-stage CTCL. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## POLICY

### ORGAN REJECTION AFTER SOLID-ORGAN TRANSPLANT

Extracorporeal photopheresis may be considered **medically necessary** to treat cardiac allograft rejection, including acute rejection, that is either recurrent or that is refractory to standard immunosuppressive drug treatment.

Extracorporeal photopheresis is considered **investigational** in all other situations related to treatment or prevention of rejection in solid-organ transplantation.

### GRAFT-VERSUS-HOST DISEASE

#### Acute

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat acute graft-versus-host disease (GVHD) that is refractory to medical therapy.

Extracorporeal photopheresis is considered **investigational** as a technique to treat acute GVHD that is either previously untreated or is responding to established therapies.

## Chronic

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat chronic GVHD that is refractory to medical therapy.

Extracorporeal photopheresis is considered **investigational** as a technique to treat chronic GVHD that is either previously untreated or is responding to established therapies.

## AUTOIMMUNE DISEASES

Extracorporeal photopheresis is considered **investigational** as a technique to treat either cutaneous or visceral manifestations of autoimmune diseases, including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, or Crohn disease.

## CUTANEOUS T-CELL LYMPHOMA

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat late-stage (III or IV) cutaneous T-cell lymphoma.

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat early stage (I or II) cutaneous T-cell lymphoma that is progressive and refractory to established nonsystemic therapies.

Extracorporeal photopheresis is considered **investigational** as a technique to treat early stage (I or II) cutaneous T-cell lymphoma that is either previously untreated or is responsive to established nonsystemic therapies.

## OTHER

Extracorporeal photopheresis is considered **investigational** for all other indications.

## POLICY GUIDELINES

### ORGAN REJECTION AFTER SOLID ORGAN TRANSPLANT

A regimen of immunosuppressive therapy is standard of care for the treatment of solid-organ rejection. Therefore, refractory rejection is defined as rejection that fails to respond adequately to a standard regimen of immunosuppressive therapy.

Recurrent allograft rejection is defined as having at least two rejection episodes after standard immunosuppressive therapy.

There is no standard schedule for extracorporeal photopheresis (ECP), and reported schedules vary by the organ type. However, most reported cardiac and lung schedules initiate therapy with two consecutive days of ECP in month one, followed by biweekly therapy on two consecutive days in months two and three, then monthly on two consecutive days in months four through six.

### GRAFT-VERSUS-HOST DISEASE

Methylprednisolone is considered first-line treatment of acute GVHD. For chronic GVHD, an alternating regimen of cyclosporine and prednisone is commonly used; other therapies include antithymocyte globulin, corticosteroid monotherapy, and cytotoxic immunosuppressive drugs such as procarbazine, cyclophosphamide, or azathioprine. Therefore, refractory disease is defined as GVHD that fails to respond adequately to a trial of any of these therapies.

Treatment schedule and duration of ECP for GVHD have not been optimally defined. Guidelines and consensus statements have generally recommended one cycle (i.e., ECP on two consecutive days) weekly for acute GVHD

and every two weeks for chronic GVHD. Treatment duration is based on clinical response; discontinuation is generally recommended for no or minimal response.

#### CUTANEOUS T-CELL LYMPHOMA STAGING

Cutaneous T-cell Lymphoma staging is based on the tumor, node, metastases (TNM) classification system (see Table PG1).

Table PG1. Cutaneous T-cell Lymphoma Staging

Stage	Tumor T, N, and M Categories
IA	T1N0M0
IB	T2N0M0
IIA	T1-2N1M1
IIB	T3N0-1M0
III	T4N0-1M0
IVA	T1-4N2-3M0
IVB	T1-4N0-3M1

#### Sézary Syndrome

According to the World Health Organization-European Organization for research and Treatment of Cancer, Sézary syndrome is defined by the triad of erythroderma, generalized lymphadenopathy, and the presence of neoplastic T-cells (Sézary cells) in the skin, lymph nodes, and peripheral blood. The International Society of Cutaneous Lymphomas recommends an absolute Sézary cell count of at least 1,000 cells per cubic millimeter, in the presence of immunophenotypical abnormalities (CD4/CD8 ratio greater than ten; loss of any or all of the T-cell antigens CD2, CD3, CD4, and CD5, or both), or the demonstration of a T-cell clone in the peripheral blood by molecular or cytogenetic methods.

#### MEDICARE ADVANTAGE

Extracorporeal photopheresis may be considered **medically necessary** for:

- Palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other therapy
- Patients with acute cardiac allograft rejection whose disease is refractory to standard immunosuppressive drug treatment; and
- Patients with chronic graft versus host disease whose disease is refractory to standard immunosuppressive drug treatment.

Use for all other conditions would be **investigational**.

#### MEDICARE ADVANTAGE POLICY GUIDELINES

Extracorporeal photopheresis for the treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation may have potential to be a benefit for Medicare Advantage members, but only when extracorporeal photopheresis is performed under coverage with evidence development (CED).

## BACKGROUND

### ORGAN REJECTION TREATMENT AFTER SOLID ORGAN TRANSPLANT

The standard treatment for organ transplant rejection is immunosuppression, with the particular regimen dictated by the organ being transplanted. As organ transplantation success rates have improved, more patients are facing the morbidity and mortality associated with immunosuppressive therapies developed to prevent rejection of the transplanted organ. Immunosuppressive therapies are used to lower the responsiveness of the recipient's immune system, decreasing the chance of rejection. Unfortunately, portions of the immune system responsible for the prevention of viral, fungal, and bacterial infection also are affected. This can, in turn, lead to serious infections, including opportunistic infections.

Although first approved for the treatment of cutaneous T-cell lymphoma (CTCL), extracorporeal photopheresis (ECP) has more recently been used as a supplement to conventional therapies in the area of solid organ transplantation.<sup>1</sup> Reports of the successful use of ECP in human cardiac transplant recipients were published in 1992<sup>2,3</sup> and use in other transplant patients followed. Although the specific mechanism of action of ECP is unknown, the reinfusion of treated leukocytes seems specifically to suppress the patient's immune response to the donor organ, although maintaining the body's ability to respond to other antigens.<sup>4</sup> The specificity of ECP to target the immune response to the transplanted organ allows ECP to decrease organ rejection without an increased risk of infection, common with immunosuppressive drugs.<sup>5</sup>

#### Graft-versus-host disease

Given that graft-versus-host disease (GVHD) is an immune-mediated disease, ECP can be used to treat GVHD after a prior allogeneic cell transplant. In fact, GVHD can be categorized in two ways: (1) as an acute disease, occurring within the first 100 days after the infusion of allogeneic cells; or (2), as a chronic disease, which develops sometime after 100 days. Acute GVHD is commonly graded from I to IV, ranging from mild disease, which is characterized by a skin rash without the involvement of the liver or gut, to grades III and IV, which are characterized by generalized erythroderma, elevated bilirubin levels, or diarrhea. Grade III acute GVHD is considered severe, and grade IV is considered life-threatening. Chronic GVHD typically presents with more diverse symptomatology resembling autoimmune diseases such as progressive systemic sclerosis, systemic lupus erythematosus, or rheumatoid arthritis. Chronic GVHD may affect the mouth, eyes, respiratory tract, musculoskeletal system, and peripheral nerves, as well as the skin, liver, or gut-the usual sites of acute GVHD.

#### Autoimmune Disease

The use of ECP as a treatment of autoimmune disease is based on the premise that pathogenic lymphocytes form an expanded clone of cells, which are damaged when exposed to ultraviolet light in the presence of agent 8-methoxypsoralen. It is hypothesized that the resulting damage induces a population of circulating suppressor T cells targeted against the light-damaged cells. It is further hypothesized that these suppressor T cells are targeted at a component of the cell that is common to the entire clone of abnormal cells (i.e., not just the light-sensitized cells), thus inducing a systemic effect. However, although scleroderma and other autoimmune diseases are associated with the presence of circulating autoantibodies, it is unknown how these antibodies are related to the pathogenesis of the disease. As discussed in this evidence review, photopheresis is not associated with consistent changes in autoantibody levels.

#### T-Cell Lymphoma

##### *Cutaneous T-Cell Lymphoma*

According to the National Cancer Institute, CTCL is a neoplasia of malignant T lymphocytes that initially presents as skin involvement. CTCL is extremely rare, with an estimated incidence of approximately 0.4 per 100,000 annually, but because most are low-grade malignancies with long survival, overall prevalence is much higher. Two

CTCL variants, mycosis fungoides and the Sézary syndrome, account for approximately 60% and 5% of new cases of CTCL, respectively.

CTCL is included in the Revised European-American Lymphoma classification as a group of low-grade T-cell lymphomas, which should be distinguished from other T-cell lymphomas that involve the skin, such as anaplastic large cell lymphoma, peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma (usually with systemic involvement), or subcutaneous panniculitis T-cell lymphoma. In addition, a number of benign or very indolent conditions can be confused with mycosis fungoides, further complicating diagnosis.

Mycosis fungoides typically progresses from an eczematous patch/plaque stage, covering less than 10% of the body surface (T1), to a plaque stage, covering 10% or more of the body surface (T2), and finally to tumors (T3) that frequently undergo necrotic ulceration. Sézary syndrome is an advanced form of mycosis fungoides with generalized erythroderma (T4) and peripheral blood involvement (B1) at presentation. The cytologic transformation from a low-grade lymphoma to a high-grade lymphoma sometimes occurs during the course of these diseases and is associated with poor prognosis. A common cause of death during the tumor phase is sepsis from *Pseudomonas aeruginosa* or *Staphylococcus aureus* caused by chronic skin infection with staphylococcus species and subsequent systemic infections.

The natural history of mycosis fungoides is typically indolent. Symptoms may present for long periods of time (mean, two-ten years) as waxing and waning cutaneous eruptions. The prognosis of patients with mycosis fungoides or Sézary syndrome is based on the extent of disease at presentation and its stage. Lymphadenopathy and involvement of peripheral blood and viscera increase in likelihood with worsening cutaneous involvement and define poor prognostic groups. Median survival after diagnosis varies by stage. Median survival in patients with stage IA disease exceeds 20 years, with most deaths in this group typically unrelated to mycosis fungoides. In contrast, median survival in patients with stage III or IV disease is less than five years; more than 50% of these patients die of their disease.

Appropriate therapy of CTCL depends on a variety of factors, including stage, the patient's overall health, and the presence of symptoms. In general, therapies can be categorized into topical and systemic treatments that include ECP. In contrast to more conventional lymphomas, CTCL is usually not curable (unless caught in its earliest stages). Thus, systemic cytotoxic chemotherapy is avoided except for advanced-stage cases. Partial or complete remission is achievable, although most patients require lifelong treatment and monitoring.

## REGULATORY STATUS

Two photopheresis systems (Therakos; now Mallinckrodt) were approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. Both systems are approved for use in ultraviolet-A irradiation treatment, in the presence of the photoactive drug 8-methoxypsoralen, of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of skin manifestations of CTCL, in persons who have not been responsive to other forms of treatment. The two systems are:

- UVAR® XTS Photopheresis System (FDA approved in 1987).
- CELLEX® (FDA approved in 2009).

Photoactive 8-methoxypsoralen (UVADEX®; Therakos; now Mallinckrodt) is FDA approved for extracorporeal administration with the UVAR® XTS or CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of CTCL unresponsive to other forms of treatment.

The use of either Therakos photopheresis system or UVADEX® for other conditions is off-label. FDA product code: LNR.



Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. *J Clin Apher.* Apr 2006;21(1):72-77. PMID 16619230
2. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. *Circulation.* Nov 1992;86(5 Suppl):II242-250. PMID 1424007
3. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. *J Heart Lung Transplant.* Jul-Aug 1992;11(4 Pt 1):746-750. PMID 1498142
4. Hivelin M, Siemionow M, Grimbert P, et al. Extracorporeal photopheresis: from solid organs to face transplantation. *Transpl Immunol.* Jul 2009;21(3):117-128. PMID 19409991
5. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J Clin Apher.* Jun 2007;22(3):106-175. PMID 17394188
6. Carlo WF, Pearce FB, George JF, et al. Single-center experience with extracorporeal photopheresis in pediatric heart transplantation. *J Heart Lung Transplant.* Jun 2014;33(6):624-628. PMID 24661684
7. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. *J Heart Lung Transplant.* Mar 2006;25(3):283-288. PMID 16507420
8. Maccherini M, Diciolla F, Laghi Pasini F, et al. Photopheresis immunomodulation after heart transplantation. *Transplant Proc.* Feb-Mar 2001;33(1-2):1591-1594. PMID 11267432
9. Dall'Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. *Int J Artif Organs.* Jan 2000;23(1):49-54. PMID 12118837
10. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. *N Engl J Med.* Dec 10 1998;339(24):1744-1751. PMID 9845709
11. Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. *Ann Transplant.* Mar 2000;5(3):44-47. PMID 11233043
12. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. *Transplantation.* Dec 15 2008;86(11):1625-1627. PMID 19077900
13. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. *J Thorac Cardiovasc Surg.* Jun 1999;117(6):1063-1069. PMID 10343253
14. Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant.* Sep 2012;31(9):950-957. PMID 22884382
15. Greer M, Dierich M, De Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. *Am J Transplant.* Apr 2013;13(4):911-918. PMID 23406373

16. Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. *Bone Marrow Transplant*. Mar 2011;46(3):426-429. PMID 20581885
17. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant*. Apr 2010;29(4):424-431. PMID 19853479
18. Urbani L, Mazzoni A, Catalano G, et al. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. *Transplant Proc*. Dec 2004;36(10):3068-3070. PMID 15686696
19. Urbani L, Mazzoni A, De Simone P, et al. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis. *J Clin Apher*. 2007;22(4):187-194. PMID 17294458
20. Urbani L, Mazzoni A, Colombatto P, et al. Potential applications of extracorporeal photopheresis in liver transplantation. *Transplant Proc*. May 2008;40(4):1175-1178. PMID 18555142
21. Jardine MJ, Bhandari S, Wyburn KR, et al. Photopheresis therapy for problematic renal allograft rejection. *J Clin Apher*. Jun 2009;24(4):161-169. PMID 19536814
22. Kumlien G, Genberg H, Shanwell A, et al. Photopheresis for the treatment of refractory renal graft rejection. *Transplantation*. Jan 15 2005;79(1):123-125. PMID 15714180
23. Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. *Transfus Apher Sci*. Jun 2002;26(3):197-204. PMID 12126206
24. Dall'Amico R, Murer L, Montini G, et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. *J Am Soc Nephrol*. Jan 1998;9(1):121-127. PMID 9440096
25. Baron ED, Heeger PS, Hricik DE, et al. Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection. *Photodermatol Photoimmunol Photomed*. Apr 2001;17(2):79-82. PMID 11338406
26. Sunder-Plassman G, Druml W, Steininger R, et al. Renal allograft rejection controlled by photopheresis. *Lancet*. Aug 19 1995;346(8973):506. PMID 7637500
27. Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. *Biol Blood Marrow Transplant*. Nov 2014;20(11):1677-1686. PMID 24867779
28. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. *Blood*. Oct 1 2008;112(7):2667-2674. PMID 18621929
29. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for graft-versus-host disease. *TEC Assessments*. 2001;Volume 16:Tab 9.
30. Hautmann AH, Wolff D, Hahn J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. *Bone Marrow Transplant*. Mar 2013;48(3):439-445. PMID 22922407
31. Ussowicz M, Musial J, Mielcarek M, et al. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Transplant Proc*. Nov 2013;45(9):3375-3380. PMID 24182819
32. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev*. 2014;2:CD009759. PMID 24569960
33. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev*. Feb 25 2014;2(2):CD009898. PMID 24569961
34. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. *Transfusion*. Jun 2010;50(6):1359-1369. PMID 20113452
35. Halle P, Paillard C, D'Incan M, et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. *J Hematother Stem Cell Res*. Jun 2002;11(3):501-512. PMID 12183835

36. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. *Transfusion*. Oct 2001;41(10):1299-1305. PMID 11606832
37. Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. *J Pediatr Hematol Oncol*. Oct 2007;29(10):678-687. PMID 17921848
38. Zhang H, Chen R, Cheng J, et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. *Patient Prefer Adherence*. Feb 2015;9:105-111. PMID 25653504
39. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. *Haematologica*. Mar 2006;91(3):405-408. PMID 16531267
40. Jagasia M, Greinix H, Robin M, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. *Biol Blood Marrow Transplant*. Jul 2013;19(7):1129-1133. PMID 23623892
41. Rubegni P, Feci L, Poggiali S, et al. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form. *Br J Dermatol*. Aug 2013;169(2):450-457. PMID 23534380
42. Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. Jun 2010;45(6):1068-1076. PMID 19915634
43. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. *Bone Marrow Transplant*. Nov 2008;42(9):609-617. PMID 18660840
44. Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. *Blood Res*. Jun 2014;49(2):100-106. PMID 25025011
45. Ontario Health Technology Advisory Committee. OHTAC Recommendation: Extracorporeal Photopheresis. 2006; [http://www.hqontario.ca/english/providers/program/ohtac/tech/recommend/rec\\_ecp\\_032806.pdf](http://www.hqontario.ca/english/providers/program/ohtac/tech/recommend/rec_ecp_032806.pdf). Accessed September 24, 2018.
46. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. *Bone Marrow Transplant*. Jun 2005;35(12):1187-1193. PMID 15852025
47. Dignan FL, Aguilar S, Scarisbrick JJ, et al. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant*. May 2014;49(5):704-708. PMID 24566709
48. Greinix HT, Volc-Platzer B, Knobler R. Criteria for assessing chronic GVHD. *Bone Marrow Transplant*. Mar 2000;25(5):575. PMID 10713639
49. Rubegni P, Cuccia A, Sbrano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. *Br J Haematol*. Jul 2005;130(2):271-275. PMID 16029456
50. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for autoimmune disease. *TEC Assessments*. 2001;Volume 16:Tab 10.
51. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. *Arch Dermatol*. Mar 1992;128(3):337-346. PMID 1550365
52. Fries JF, Seibold JR, Medsger TA, Jr. Photopheresis for scleroderma? No! *J Rheumatol*. Jul 1992;19(7):1011-1013. PMID 1512753
53. Melski JW. Price of technology. A blind spot. *JAMA*. Mar 18 1992;267(11):1516-1518. PMID 1538542
54. Trentham DE. Photochemotherapy in systemic sclerosis. The stage is set. *Arch Dermatol*. Mar 1992;128(3):389-390. PMID 1550373
55. Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. *Clin Immunol*. Feb 2012;142(2):150-159. PMID 22036269

56. Cavaletti G, Perseghin P, Dassi M, et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. *Neurol Sci.* Apr 2006;27(1):24-32. PMID 16688596
57. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. *Arch Dis Child.* Aug 2001;85(2):149-154. PMID 11466190
58. Sanli H, Akay BN, Ayyildiz E, et al. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. *Transfus Apher Sci.* Dec 2010;43(3):353-359. PMID 21035398
59. Rubegni P, Poggiali S, Cevenini G, et al. Long term follow-up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. *J Eur Acad Dermatol Venereol.* Apr 2013;27(4):523-526. PMID 22540319
60. Wolf P, Georgas D, Tomi NS, et al. Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. *Photochem Photobiol Sci.* Jan 2013;12(1):174-181. PMID 22948099
61. Reinisch W, Knobler R, Rutgeerts PJ, et al. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial. *Inflamm Bowel Dis.* Feb 2013;19(2):293-300. PMID 22573600
62. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. *N Engl J Med.* Feb 5 1987;316(6):297-303. PMID 3543674
63. Knobler R, Duvic M, Querfeld C, et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatol Photoimmunol Photomed.* Oct 2012;28(5):250-257. PMID 22971190
64. Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. *J Cutan Med Surg.* Sep-Oct 2006;10(5):228-233. PMID 17234106
65. Keehn CA, Belongie IP, Shistik G, et al. The diagnosis, staging, and treatment options for mycosis fungoides. *Cancer Control.* Apr 2007;14(2):102-111. PMID 17387295
66. Knobler E. Current management strategies for cutaneous T-cell lymphoma. *Clin Dermatol.* May-Jun 2004;22(3):197-208. PMID 15262305
67. Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. *Clin Exp Dermatol.* Mar 2006;31(2):181-186. PMID 16487086
68. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. *Cancer Treat Rev.* Apr 2007;33(2):146-160. PMID 17275192
69. Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. *Br J Dermatol.* Apr 2008;158(4):659-678. PMID 18241274
70. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. *Eur J Cancer.* May 2006;42(8):1014-1030. PMID 16574401
71. Whittaker SJ, Marsden JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. *Br J Dermatol.* Dec 2003;149(6):1095-1107. PMID 14696593
72. National Cancer Institute. Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)-Health Professional Version. 2018; <https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq?re-direct=true>. Accessed September 24, 2018.
73. Miller JD, Kirkland EB, Domingo DS, et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. *Photodermatol Photoimmunol Photomed.* Oct 2007;23(5):163-171. PMID 17803594
74. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood.* May 15 2005;105(10):3768-3785. PMID 15692063

75. Das-Gupta E, Dignan F, Shaw B, et al. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. *Bone Marrow Transplant*. Oct 2014;49(10):1251-1258. PMID 24887389
76. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Aug 2012;18(8):1150-1163. PMID 22510384
77. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. *Br J Haematol*. Jul 2003;122(1):118-127. PMID 12823353
78. Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. *Br J Haematol*. Jul 2012;158(1):30-45. PMID 22533831
79. Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. *Br J Haematol*. Jul 2012;158(1):46-61. PMID 22533811
80. Das-Gupta E, Watson LB, J., Russell N. Physicians Poster Sessions. P503: a single-centre experience of the efficacy of extracorporeal photopheresis in the treatment of steroid-refractory acute graft-versus-host disease. *Bone Marrow Transplant*. 2011;46(S1):S114.
81. Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. *Transfusion*. Oct 2013;53(10):2340-2352. PMID 23305044
82. National Cancer Institute. Childhood Hematopoietic Cell Transplantation (PDQ®)-Health Professional Version. 2018; <https://www.cancer.gov/types/childhood-cancers/child-hct-hp-pdq#section/all?redirect=true>. Accessed September 24, 2018.
83. Bredeson C, Rumble RB, Varela NP, et al. Extracorporeal photopheresis in the management of graft-versus-host disease. *Curr Oncol*. Apr 2014;21(2):e310-325. PMID 24764713
84. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines on oncology: T-cell lymphomas. Version 5.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/t-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf). Accessed September 24, 2018.
85. Center for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4). 2012; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=113&ncdver=3&bc=AAAAgAAAAAAAAAA%3d%3d&>. Accessed September 24, 2018.